Harbi Emirhan, Yarar Erhan, Mason Christopher E, Aschner Michael, Altundag Aytug
Faculty of Engineering and Natural Sciences, Bahcesehir University, Istanbul, Turkey.
Emeritus Member, The International Cannabinoid Research Society (ICRS), Winston-Salem, NC, USA.
Neurochem Res. 2025 Jul 29;50(4):254. doi: 10.1007/s11064-025-04505-9.
Glioblastoma is the most aggressive and fatal primary brain tumor in adults, characterized by poor prognosis and limited treatment efficacy due to the impermeability of the blood-brain barrier (BBB) and its treatment-resistant nature. This review aims to evaluate the potential of intranasal terpene treatment (ITT) as a novel and non-invasive strategy to bypass the BBB and improve glioblastoma treatment outcomes. A review of recent preclinical and clinical studies on intranasally administered compounds (especially terpenes such as Perillyl alcohol (POH)) is presented in terms of their molecular mechanisms, bioavailability, and clinical effects in the central nervous system (CNS).
胶质母细胞瘤是成人中最具侵袭性和致命性的原发性脑肿瘤，其特点是预后差且治疗效果有限，这是由于血脑屏障（BBB）的不可渗透性及其抗治疗性。本综述旨在评估鼻内萜类治疗（ITT）作为一种新颖的非侵入性策略绕过血脑屏障并改善胶质母细胞瘤治疗结果的潜力。本文回顾了近期关于经鼻给药化合物（特别是萜类，如紫苏醇（POH））的临床前和临床研究，涉及它们在中枢神经系统（CNS）中的分子机制、生物利用度和临床效果。
